@article{3159121,
    title = "Do type 1 receptor tyrosine kinases inform treatment choice? A
prospectively planned analysis of the TEAM trial",
    author = "Bartlett, J. M. S. and Brookes, C. L. and Piper, T. and van de Velde, C. and J. H. and Stocken, D. and Lyttle, N. and Hasenburg, A. and Quintayo, M. and A. and Kieback, D. G. and Putter, H. and Markopoulos, C. and Kranenbarg, and E. M-K and Mallon, E. A. and Dirix, L. Y. and Seynaeve, C. and Rea, D. and W.",
    journal = "British Journal of Cancer",
    year = "2013",
    volume = "109",
    number = "9",
    pages = "2453-2461",
    publisher = "Nature Publishing Group",
    issn = "0007-0920, 1532-1827",
    doi = "10.1038/bjc.2013.609",
    abstract = "Background: Epidermal growth factor receptors contribute to breast
cancer relapse during endocrine therapy. Substitution of aromatase
inhibitors (AIs) may improve outcomes in HER-positive cancers.
Methods: Tissue microarrays were constructed. Quantitative analysis of
HER1, HER2, and HER3 was performed. Data were analysed relative to
disease-free survival and treatment using outcomes at 2.75 and 6.5
years.
Results: Among 4541 eligible samples, 4225 (93%) had complete HER1-3
data. Overall, 5% were HER1-positive, 13% HER2positive, and 21%
HER3-positive; 32% (n = 1351) overexpressed at least one HER receptor.
In the HER1-3-negative subgroup, the hazard ratio (HR) for upfront
exemestane vs tamoxifen at 2.75 years was 0.67 (95% confidence interval
(CI), 0.52-0.87), in the HER1-3-positive subgroup, the HR was 1.15 (95%
CI, 0.85-1.56). A prospectively planned treatment-by-marker analysis
demonstrated a significant interaction between HER1-3 and treatment at
2.75 years (HR 0.58; 95% CI, 0.39-0.87; P 0.008), as confirmed by
multivariate regression analysis adjusting for prognostic factors (HR
0.55; 95% CI, 0.36-0.85; P 0.005). This effect was time dependent.
Conclusion: In the 2.75 years prior to switching patients initially
treated with tamoxifen to exemestane, a significant treatmentby- marker
effect exists between AI/tamoxifen treatment and HER1-3 expression,
suggesting HER expression could be used to select appropriate endocrine
treatment at diagnosis to prevent or delay early relapses."
}